<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">patmedfar</journal-id><journal-title-group><journal-title xml:lang="ru">Пациентоориентированная медицина и фармация</journal-title><trans-title-group xml:lang="en"><trans-title>Patient-Oriented Medicine and Pharmacy</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-1924</issn><publisher><publisher-name>LLC Izdatelstvo OKI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2949-1924-0004</article-id><article-id custom-type="elpub" pub-id-type="custom">patmedfar-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВНУТРЕННИЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INTERNAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Особенности клинико-лабораторных показателей у больных с хронической сердечной недостаточностью пожилого и старческого возраста при дефиците железа</article-title><trans-title-group xml:lang="en"><trans-title>Characteristics of clinical and laboratory parameters in patients with chronic heart failure of elderly and senile age with iron deficiency</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8988-998X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смирнова Марина Петровна — к. м. н., доцент кафедры факультетской терапии</p><p>eLibrary SPIN-код: 4399-0900</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Smirnova Marina P. — Candidate of Medical Sciences, Associate Professor, Department of Faculty Therapy</p><p>eLibrary SPIN: 4399-0900</p><p>Yaroslavl</p></bio><email xlink:type="simple">msm76-743@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7969-6538</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чижов</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Chizhov</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чижов Пётр Александрович — д. м. н., проф., зав. кафедрой факультетской терапии</p><p>eLibrary SPIN-код: 6427-4298</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Chizhov Petr A. — Doctor of Medical Sciences, Prof., Head. Department of Faculty Therapy</p><p>eLibrary SPIN: 6427-4298</p><p>Yaroslavl</p></bio><email xlink:type="simple">p.chizhov63@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1231-9564</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корсакова</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Korsakova</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Корсакова Дарья Александровна — аспирант кафедры факультетской терапии</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Korsakova Daria A. — graduate student, Department of Faculty Therapy</p><p>Yaroslavl</p></bio><email xlink:type="simple">dasha.kudrjavceva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7847-1679</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баранов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baranov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Баранов Андрей Анатольевич — д. м. н., проф., зав. кафедрой поликлинической терапии, клинической лабораторной диагностики и медицинской биохимии</p><p>eLibrary SPIN-код: 4497-7008</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Baranov Andrey A. — Doctor of Medical Sciences, Prof., Head. Department of Polyclinic Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry</p><p>eLibrary SPIN: 4497-7008</p><p>Yaroslavl</p></bio><email xlink:type="simple">bara_aa@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Ярославский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education «Yaroslavl State Medical University» of the Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>02</day><month>02</month><year>2023</year></pub-date><volume>1</volume><issue>1</issue><fpage>23</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Смирнова М.П., Чижов П.А., Корсакова Д.А., Баранов А.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Смирнова М.П., Чижов П.А., Корсакова Д.А., Баранов А.А.</copyright-holder><copyright-holder xml:lang="en">Smirnova M.P., Chizhov P.A., Korsakova D.A., Baranov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pomph.ru/jour/article/view/9">https://www.pomph.ru/jour/article/view/9</self-uri><abstract><p>Актуальность. Частота хронической сердечной недостаточности (ХСН) увеличивается с возрастом. Распространённой патологией у больных с ХСН является дефицит железа (ДЖ). Развитию ДЖ у больных с ХСН может способствовать возраст. Цель исследования: сопоставить особенности клинических и лабораторных показателей у пациентов с ХСН пожилого и старческого возраста в зависимости от наличия ДЖ. Материалы и методы: обследовано 2 группы больных с ХСН 2-4-го функционального класса: 1-я группа — 60-74 года (146 больных, средний возраст 68,1±3,1), 2-я группа — 75 лет и старше (127 пациентов, средний возраст 78,3±2,2). У всех больных проводили клиническое обследование, тест 6-минутной ходьбы, общий анализ крови, определение в сыворотке крови уровня железа, ферритина, трансферрина, насыщения трансферрина железом, растворимых рецепторов трансферрина, гепсидина, интерлейкина-6, С-реактивного белка, наличия и выраженности астении, тревоги, депрессии. Результаты. Установлено, что больные старческой группы имеют достоверно большую выраженность латентного ДЖ и более выраженные клинико-лабораторные проявления ХСН (меньшую дистанцию теста 6-минутной ходьбы, более выраженные проявления астении и депрессии, большую концентрацию NT-proBNP, гепсидина), по сравнению с пожилыми больными. Наличие ДЖ в обеих возрастных группах усиливает проявления физической астении и тревоги. Выводы: 1) выраженность клинических проявлений ХСН у больных старческого возраста достоверно больше, чем у пожилых пациентов; 2) у больных старческого возраста достоверно выше, чем у пожилых пациентов, уровень гепсидина и выраженность латентного ДЖ; 3) латентный ДЖ в обеих возрастных группах усиливает проявления физической астении и тревоги; 4) целесообразно проведение ранней диагностики латентного ДЖ у всех больных с ХСН пожилого и особенно старческого возраста для своевременного выявления данного состояния и назначения терапии для коррекции ДЖ.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. The frequency of chronic heart failure (CHF) increases with age. A common pathology in patients with CHF is iron deficiency (ID). Age may contribute to development of ID in patients with CHF. The purpose of the study: To study the features of clinical and laboratory parameters in elderly and senile patients with CHF, depending on the presence of ID. Materials and methods: 2 groups of patients with CHF 2-4 functional class were examined: group 1-60-74 years (146 patients, mean age 68.1±3.1), group 2-75 years and older (127 patients, mean age 78.3±2.2). All patients underwent a clinical examination, a 6-minute walk test, a general blood test, the determination of the level of iron, ferritin, transferrin in blood serum, iron saturation of transferrin, soluble transferrin receptors, hepcidin, interleukin-6, C-reactive protein, the presence and severity of asthenia, anxiety, depression. Results. It has been established that patients in the senile group have a significantly higher functional life expectancy and more pronounced clinical and laboratory manifestations of CHF (the worst 6-minute walk test, more pronounced manifestations of asthenia and depression, a higher concentration of NT-proBNP, hepcidin), compared with elderly patients. The presence of ID in both age groups increases the manifestations of physical asthenia and anxiety. Conclusions: 1) the severity of clinical manifestations of CHF in senile patients is significantly higher than in elderly patients; 2) in senile patients, the levels of hepcidin and latent ID are significantly higher than those in elderly patients; 3) latent ID in both age groups increases the manifestations of physical asthenia and anxiety; 4) it is advisable to conduct early diagnosis of latent ID in all patients with CHF of elderly and, especially, senile age for the timely detection of this condition and the appointment of therapy for correcting ID.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>пожилой и старческий возраст</kwd><kwd>дефицит железа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>elderly and senile age</kwd><kwd>iron deficiency</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнялась без спонсорской поддержки.</funding-statement><funding-statement xml:lang="en">The work was carried out without sponsorship.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42:3599-726. doi: 10.1093/eurheartj/ehab368</mixed-citation><mixed-citation xml:lang="en">2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42:3599-726. doi: 10.1093/eurheartj/ehab368</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации ОССН — РКО — РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58 (S6):8-164. doi: 10.18087/cardio.2475.</mixed-citation><mixed-citation xml:lang="en">Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiya. 2018;58 (S6):8-164. (In Russ.). doi: 10.18087/cardio.2475.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kurz K, Lanser L, Seifert M et al. Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure. ESC Heart Failure. 2020;7:1880-90. Published online 27 May 2020 in Wiley Online Library (wileyonlinelibrary.com). doi: 10.1002/ehf2.12755</mixed-citation><mixed-citation xml:lang="en">Kurz K, Lanser L, Seifert M et al. Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure. ESC Heart Failure. 2020;7:1880-90. Published online 27 May 2020 in Wiley Online Library (wileyonlinelibrary.com). doi: 10.1002/ehf2.12755</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Moliner P, Enjuanes C, Tajes M et al. Association between norepinephrine levels and abnormal iron status in patients with chronic heart failure: is iron deficiency more than a comorbidity? J Am Heart Assoc. 2019 Feb 19;8 (4):e010887. doi: 10.1161/JAHA.118.010887</mixed-citation><mixed-citation xml:lang="en">Moliner P, Enjuanes C, Tajes M et al. Association between norepinephrine levels and abnormal iron status in patients with chronic heart failure: is iron deficiency more than a comorbidity? J Am Heart Assoc. 2019 Feb 19;8 (4):e010887. doi: 10.1161/JAHA.118.010887</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Beattie JM, Khatib R, Phillips CJ, Williams SJ. Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study. Open Heart. 2020 Mar 11;7 (1):e001153. doi: 10.1136/openhrt-2019-001153</mixed-citation><mixed-citation xml:lang="en">Beattie JM, Khatib R, Phillips CJ, Williams SJ. Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study. Open Heart. 2020 Mar 11;7 (1):e001153. doi: 10.1136/openhrt-2019-001153</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">von Haehling S, Ebner N, Evertz R et al. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019 Jan;7 (1):36-46. doi: 10.1016/j.jchf.2018.07.015</mixed-citation><mixed-citation xml:lang="en">von Haehling S, Ebner N, Evertz R et al. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019 Jan;7 (1):36-46. doi: 10.1016/j.jchf.2018.07.015</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jankowska EA, Tkaczyszyn M, Suchocki Tet al. Effects of intravenous iron therapy in irondeficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18:786-95. doi: 10.1002/ejhf.473</mixed-citation><mixed-citation xml:lang="en">Jankowska EA, Tkaczyszyn M, Suchocki Tet al. Effects of intravenous iron therapy in irondeficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18:786-95. doi: 10.1002/ejhf.473</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Anker SD, Kirwan BA, van Veldhuisen DJ et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data metaanalysis. Eur J Heart Fail. 2018;20:125-33. doi: 10.1002/ejhf.823</mixed-citation><mixed-citation xml:lang="en">Anker SD, Kirwan BA, van Veldhuisen DJ et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data metaanalysis. Eur J Heart Fail. 2018;20:125-33. doi: 10.1002/ejhf.823</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнова М. П., Чижов П. А., Баранов А. А. Эффективность внутривенного введения железа (III) гидроксид сахарозного комплекса у пациентов с хронической сердечной недостаточностью с сохранённой фракцией выброса и дефицитом железа. Вестник современной клинической медицины. 2022;15 (5):66-72. doi: 10.20969/VSKM.2022.15(5).66-72.</mixed-citation><mixed-citation xml:lang="en">Smirnova MP, Chizhov PA, Baranov AA. Effectivness of intravenous administration of iron (III) sucrose complex hydroxide in patients with chronic heart failure with preserved ejection fraction and iron deficiency. Vestnik sovremennoi klinicheskoi mediciny. 2022;15 (5):66-72. (In Russ.). doi: 10.20969/VSKM.2022.15(5).66-72.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rizzo C, Carbonara R, Ruggieri R et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;8:709872. doi: 10.3389/fcvm.2021.709872</mixed-citation><mixed-citation xml:lang="en">Rizzo C, Carbonara R, Ruggieri R et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;8:709872. doi: 10.3389/fcvm.2021.709872</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Соломахина Н. И., Находнова Е. С., Ершов В. И., Беленков Ю. Н. Роль гепсидина в формировании анемии хронических заболеваний и железодефицитной анемии у больных с хронической сердечной недостаточностью в пожилом и старческом возрасте. Кардиология. 2018;58 (3):20-7. doi: 10.18087/cardio.2018.3.10094.</mixed-citation><mixed-citation xml:lang="en">Solomahina NI, Nahodnova ES, Ershov VI, Belenkov JuN. The role of hepcidin in the formation of anemia of chronic diseases and iron deficiency anemia in patients with chronic heart failure in the elderly and senile age. Kardiologiya. 2018;58 (3):20-7. (In Russ.). doi: 10.18087/cardio.2018.3.10094.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ватутин Н. Т., Тарадин Г. Г., Канишева И. В., Венжега В. В. Анемия и железодефицит у больных с хронической сердечной недостаточностью. Кардиология. 2019;59 (4S): 4-20. doi: 10.18087/cardio.2638.</mixed-citation><mixed-citation xml:lang="en">Vatutin NT, Taradin GG, Kanisheva IV, Venzhega VV. Anemia and iron deficiency in patients with chronic heart failure. Kardiologiya. 2019;59 (4S): 4-20. (In Russ.). doi: 10.18087/cardio.2638.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Стуклов Н. И. Дефицит железа и анемия у больных хронической сердечной недостаточностью. Рациональная фармакотерапия в кардиологии. 2017;13 (5):651-60. doi: 10.20996/1819-6446-2017-13-5-651-660.</mixed-citation><mixed-citation xml:lang="en">Stuklov NI. Iron deficiency and anemia in patients with chronic heart failure. Racionalnaja farmacoterapija v kardiologii. 2017;13 (5):651-60. (In Russ.). doi: 10.20996/1819-6446-2017-13-5-651-660.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Galy B, Ferring-Appel D, Sauer SW et al. Iron regulatory proteins secure mitochondrial iron sufficiency and function. Cell Metab. 2010;12:194-201.</mixed-citation><mixed-citation xml:lang="en">Galy B, Ferring-Appel D, Sauer SW et al. Iron regulatory proteins secure mitochondrial iron sufficiency and function. Cell Metab. 2010;12:194-201.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hower V, Mendes P, Torti FM et al. A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst. 2009;5:422-43.</mixed-citation><mixed-citation xml:lang="en">Hower V, Mendes P, Torti FM et al. A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst. 2009;5:422-43.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hoes MF, Grote BN, Kijlstra JD et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail. 2018;20:910-9. doi: 10.1002/ejhf.1154</mixed-citation><mixed-citation xml:lang="en">Hoes MF, Grote BN, Kijlstra JD et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail. 2018;20:910-9. doi: 10.1002/ejhf.1154</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Rizzo C, Carbonara R, Ruggieri R et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;8:709872. doi: 10.3389/fcvm.2021.709872</mixed-citation><mixed-citation xml:lang="en">Rizzo C, Carbonara R, Ruggieri R et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;8:709872. doi: 10.3389/fcvm.2021.709872</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Maeder MT, Khammy O, Remrdios C, Kaye DM. Myocardial and systemic iron depletion in heart failure: implicatins for anemia accompanying heart failure. J Am Coll Cardiol. 2011;58 (5):474-80. doi: 10.1016/j.jacc.2011.01.059</mixed-citation><mixed-citation xml:lang="en">Maeder MT, Khammy O, Remrdios C, Kaye DM. Myocardial and systemic iron depletion in heart failure: implicatins for anemia accompanying heart failure. J Am Coll Cardiol. 2011;58 (5):474-80. doi: 10.1016/j.jacc.2011.01.059</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Philip Saltiel PhF, Silverstein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuripsychiatric Disease and Treatment. 2015;11:8750888. doi: 10.2147/NDT.S73261</mixed-citation><mixed-citation xml:lang="en">Philip Saltiel PhF, Silverstein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuripsychiatric Disease and Treatment. 2015;11:8750888. doi: 10.2147/NDT.S73261</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nnah IC, Wessling-Resnick M. Brain Iron Homeostasis: A Focus on microglial. Iron Pharmaceuticals (Basel). 2018;11 (4):129-55. doi: 10.3390/ph11040129</mixed-citation><mixed-citation xml:lang="en">Nnah IC, Wessling-Resnick M. Brain Iron Homeostasis: A Focus on microglial. Iron Pharmaceuticals (Basel). 2018;11 (4):129-55. doi: 10.3390/ph11040129</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
